CERC 301

Drug Profile

CERC 301

Alternative Names: CERC-301; MK-0657

Latest Information Update: 20 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Developer Cerecor; Merck & Co
  • Class Amines; Antiparkinsonians; Esters; Piperidines; Pyrimidines
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder
  • Discontinued Parkinson's disease

Most Recent Events

  • 01 Dec 2016 Cerecor Inc completes a phase II trial in Major depressive disorder (Adjunctive treatment) in USA (NCT02459236)
  • 29 Nov 2016 Safety and efficacy data from a phase II trial in Major depressive disorder released by Cerecor
  • 21 Sep 2016 Cerecor completes enrolment in its phase II trial for major depressive disorder in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top